Health Blueprint

Back to Longevity News

News summary

Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies

Source: PR Newswire • Published: 26 Oct 2026, 22:03

Summarized by Masters of Longevity from PR Newswire.

Kos invested in Golden Age Health to scale rare disease commercial access in Asia.

Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
Key Takeaways
  • Kos invested via its inaugural Kos BioVentures fund.
  • Alex Tzoukas was named to Golden Age Health's board.
  • Funding will support GAH expansion across Greater China and Asia‑Pacific.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?